Core Viewpoint - Cannabis stocks have underperformed over the past five years, but recent positive regulatory changes in the U.S. may present long-term growth opportunities if the marijuana market expands significantly [1] Group 1: Canopy Growth - Canopy Growth is a leading player in the Canadian cannabis market with a diverse product portfolio, including dried cannabis flower, vapes, and edibles, and has a presence in multiple countries, including the U.S. [2] - Following President Trump's executive order to classify cannabis as a Schedule III substance, Canopy Growth may have expansion opportunities in the U.S. [3] - In Q3 2026, Canopy Growth reported net revenue of $54.62 million, a slight decrease of 0.3% year-over-year, but improved its net loss per share to $0.13 from $0.81 in the previous year [3] - If Canopy Growth can capitalize on U.S. opportunities and continue to reduce losses, it could yield strong returns [4] Group 2: Tilray Brands - Tilray Brands also has a comprehensive portfolio of cannabis products and operates in several countries, including the U.S., Germany, and Portugal, and has diversified into craft brewing and hemp-based products [5] - In Q2 of its 2026 fiscal year, Tilray reported net revenue of $217.5 million, a 3% year-over-year increase, while its net loss improved to $0.41 from $0.99 in the previous year [6] - Tilray is well-positioned to take advantage of emerging opportunities in the U.S. cannabis market, which could lead to significant share price increases if successful [6]

Core Insights - Canopy Growth's stock is trading at less than $2, raising questions about its attractiveness as an investment given the current market conditions [1] Group 1: Market Performance - Canopy Growth is one of the largest cannabis producers in Canada, with a diverse product portfolio including dried cannabis, vapes, and cannabis-infused drinks [3] - The Canadian cannabis market has been disappointing, with limited growth opportunities, significant competition, and ongoing legal and regulatory challenges affecting all Canadian cannabis companies [4] - The overall cannabis industry in Canada has experienced slow revenue growth and consistent net losses, indicating systemic issues rather than company-specific problems [5] Group 2: U.S. Market Dynamics - Recent developments in the U.S. cannabis market, such as the reclassification of cannabis by President Trump, may improve conditions for U.S. cannabis companies but are unlikely to benefit Canopy Growth significantly [5][6] - Cannabis remains illegal at the federal level in the U.S., creating challenges for companies, including high operational costs and difficulties in profitability [7] - Canopy Growth's U.S. subsidiary will face intense competition, similar to what it experiences in Canada, limiting its potential for recovery [7]